266 related articles for article (PubMed ID: 35211490)
1. Mutation of MUC16 Is Associated With Tumor Mutational Burden and Lymph Node Metastasis in Patients With Gastric Cancer.
Zhang F; Li X; Chen H; Guo J; Xiong Z; Yin S; Jin L; Chen X; Luo D; Tang H; Mao C; Lian L
Front Med (Lausanne); 2022; 9():836892. PubMed ID: 35211490
[TBL] [Abstract][Full Text] [Related]
2. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer.
Li X; Pasche B; Zhang W; Chen K
JAMA Oncol; 2018 Dec; 4(12):1691-1698. PubMed ID: 30098163
[TBL] [Abstract][Full Text] [Related]
3. Effect of
Wang Z; Hou H; Zhang H; Duan X; Li L; Meng L
Am J Transl Res; 2022; 14(2):849-862. PubMed ID: 35273689
[TBL] [Abstract][Full Text] [Related]
4. Mining The Cancer Genome Atlas database for tumor mutation burden and its clinical implications in gastric cancer.
Zhao DY; Sun XZ; Yao SK
World J Gastrointest Oncol; 2021 Jan; 13(1):37-57. PubMed ID: 33510848
[TBL] [Abstract][Full Text] [Related]
5. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer.
Cheng Y; Bu D; Zhang Q; Sun R; Lyle S; Zhao G; Dong L; Li H; Zhao Y; Yu J; Hao X
J Adv Res; 2023 Sep; 51():121-134. PubMed ID: 36351537
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.
Ma W; Li W; Xu L; Liu L; Xia Y; Yang L; Da M
Pathol Oncol Res; 2021; 27():1609852. PubMed ID: 34566519
[No Abstract] [Full Text] [Related]
7. Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study.
Liu T; Wu L; Liu J; Chen H; Zhu B; Qiao D; Zhu Y; Liu T; Chen Q; Hu A
Medicine (Baltimore); 2023 Nov; 102(44):e35481. PubMed ID: 37932988
[TBL] [Abstract][Full Text] [Related]
8. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
9. The Association of
Wang X; Yu X; Krauthammer M; Hugo W; Duan C; Kanetsky PA; Teer JK; Thompson ZJ; Kalos D; Tsai KY; Smalley KSM; Sondak VK; Chen YA; Conejo-Garcia JR
Cancer Epidemiol Biomarkers Prev; 2020 Sep; 29(9):1792-1799. PubMed ID: 32611582
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of MUC16 Mutation and Its Correlation with Immunity in Hepatocellular Carcinoma Patients.
Liu B; Dong Z; Lu Y; Ma J; Ma Z; Wang H
Evid Based Complement Alternat Med; 2022; 2022():3478861. PubMed ID: 36034941
[TBL] [Abstract][Full Text] [Related]
11.
Huang T; Liang Y; Zhang H; Chen X; Wei H; Sun W; Wang Y
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828321
[TBL] [Abstract][Full Text] [Related]
12. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.
Wang D; Wang N; Li X; Chen X; Shen B; Zhu D; Zhu L; Xu Y; Yu Y; Shu Y
Gastric Cancer; 2021 Jul; 24(4):823-834. PubMed ID: 33687617
[TBL] [Abstract][Full Text] [Related]
13. CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients.
Lu N; Liu J; Xu M; Liang J; Wang Y; Wu Z; Xing Y; Diao F
Int J Gen Med; 2021; 14():7647-7657. PubMed ID: 34764678
[TBL] [Abstract][Full Text] [Related]
14. Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy.
Li Z; Jia Y; Zhu H; Xing X; Pang F; Shan F; Li S; Wang D; Zhao F; Ma T; Wang S; Ji J
Gastric Cancer; 2021 Nov; 24(6):1342-1354. PubMed ID: 34406546
[TBL] [Abstract][Full Text] [Related]
15. Fatty Acid Metabolism Signature Contributes to the Molecular Diagnosis of a Malignant Gastric Cancer Subtype with Poor Prognosis and Lower Mutation Burden.
Chen Z; Cheng G
Recent Pat Anticancer Drug Discov; 2023 Sep; ():. PubMed ID: 37691229
[TBL] [Abstract][Full Text] [Related]
16. Mucin 4 mutation is associated with tumor mutation burden and promotes antitumor immunity in colon cancer patients.
Peng L; Li Y; Gu H; Xiang L; Xiong Y; Wang R; Zhou H; Wang J
Aging (Albany NY); 2021 Mar; 13(6):9043-9055. PubMed ID: 33714943
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of tumor mutation burden and immune microenvironment in gastric cancer.
Yu J; Zhang Q; Wang M; Liang S; Huang H; Xie L; Cui C; Yu J
Biosci Rep; 2021 Feb; 41(2):. PubMed ID: 33492335
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite Instability-Related
Zhao L; Zhang J; Qu X; Yang Y; Gong Z; Yang Y; Wu Z; Guo W
Onco Targets Ther; 2020; 13():3809-3821. PubMed ID: 32440149
[TBL] [Abstract][Full Text] [Related]
19. Association between tumor mutation burden and immune infiltration in ovarian cancer.
Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S
Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611
[TBL] [Abstract][Full Text] [Related]
20. Development and verification of a microsatellite instability-related risk signature for predicting survival and therapy effectiveness in gastric cancer.
Zhang T; Yu S; Zhao S
J Gastrointest Oncol; 2022 Feb; 13(1):84-101. PubMed ID: 35284118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
